← Hims Hers Health overview

Hims Hers Health vs Laboratory Corporation of America: why the prices moved differently

Weekly · monthly · quarterly news summaries, side by side in time

Hims Hers Health Inc (HIMS)

Q3 2026
▲2▼2

Hims & Hers grew fast but faced FTC suit and rising losses

  • Strong revenue and subscriber growth Q2 revenue jumped 38% to $753.2 million and subscribers rose 18.5% to about 2.9 million, prompting management to raise full-year guidance to $3.1–3.3 billion. This top-line momentum showed the business is still expanding quickly.

    It explains the main positive force behind the stock during the quarter.

  • GLP-1 traction and international expansion Barclays raised its price target to $39, citing traction in GLP-1 weight-loss drugs, helped by the Novo Nordisk partnership and the Eucalyptus acquisition that expanded Hims into the UK, Australia, and Canada.

    It highlights analyst optimism and new growth avenues that supported the stock.

  • FTC lawsuit over data and billing The Federal Trade Commission sued Hims over health-data sharing and deceptive billing, causing the stock to drop about 14.7% and triggering multiple law-firm investigations. This legal risk weighed heavily on investor sentiment.

    It was the biggest negative event that moved the stock during the quarter.

  • Profitability deteriorated Hims reported a $0.37 per-share loss, gross margin fell to about 64%, free cash flow was negative $68 million, and an $81 million Eucalyptus charge hit results. Visa dispute-monitoring and weight-loss cost pressures added more uncertainty.

    It shows the financial counterweight that offset strong revenue growth.

August 2026
▼2▲1

Hims & Hers Q2 revenue beats but losses and legal risks weigh

  • Strong Q2 revenue growth and raised guidance Hims & Hers reported Q2 2026 revenue up 38% to $753.2 million, beating estimates, with subscribers rising 18.5% to about 2.9 million. Management raised full-year revenue guidance to $3.1–3.3 billion, signaling confidence in demand.

    This is the main positive fundamental driver for the period, showing the business is still growing quickly.

  • Profitability deteriorated sharply The company swung to a $0.37 per-share loss, gross margin fell to about 64% from 76%, operating expenses rose 48%, and free cash flow was negative $68 million. An $81 million Eucalyptus-related charge and weight-loss strategy shift drove the miss.

    This explains the sharp negative reaction in the stock despite strong revenue, as investors focused on losses and cash burn.

  • Escalating legal and billing risks Visa's dispute-monitoring program could bring a $75,000 penalty and a 1.5% dispute cap. The FTC and state legal actions are escalating, and a consumer class action adds to the legal overhang, threatening fines and reputational damage.

    These legal and payment risks are new developments that weigh on the stock and could hurt future growth.

  • Weight-loss market cost pressures and cheaper GLP-1 potential Cost pressures in the weight-loss market are a headwind, but cheaper GLP-1 pricing could boost demand. The balance between pricing pressure and volume growth remains uncertain, keeping the stock volatile.

    This captures the mixed impact of pricing trends on demand and margins, a key uncertainty for the period.

Latest
▼3▲1

Visa billing crackdown and FTC lawsuit hit HIMS; growth stays strong

  • Visa puts HIMS in dispute-monitoring program Visa placed Hims & Hers in its Acquirer Monitoring Program after a surge in credit-card disputes tied to weight-loss subscriptions, with a possible $75,000 penalty and a requirement to keep disputes below 1.5% for three months. This threatens billing reliability and could slow subscriber growth, pushing the stock down.

    This is the main new negative event this period and directly pressures HIMS's price.

  • FTC and state regulators escalate legal action The FTC and state regulators filed a civil enforcement action, and a consumer class action targets privacy and subscription practices. The CEO says the FTC misunderstands the company, but the legal fight adds costs and reputational risk that weigh on the stock.

    This is a new escalation of the legal pressure that is a core driver of HIMS's risk profile.

  • Q2 revenue jumps 38% and outlook raised Hims & Hers raised its 2026 revenue outlook to $3.1–$3.3 billion after Q2 sales rose 38.2% to $753.2 million, beating estimates. Subscribers grew 18.5% to about 2.9 million, showing demand is still strong and supporting the stock.

    This is the main new positive fundamental update this period and shows the growth story remains intact.

  • Margins shrink and cash burn deepens Gross margin fell to 63.8% from 76%, operating expenses rose 48.4%, and free cash flow was negative $68 million with an $86.3 million net loss. The company is spending heavily to grow, which pressures profits and keeps the stock volatile.

    This is the key counterweight to the revenue beat and explains why the stock still faces pressure.

▼2

HIMS Q2 loss and margin hit overshadow revenue beat

  • Q2 loss and margin collapse Hims & Hers reported a second-quarter loss of $0.37 per share, swinging from a $0.17 profit a year earlier. Gross margin fell to 64% from 76%, hit by an $81 million one-time cost tied to the Eucalyptus acquisition, a weight-loss strategy shift, and FTC legal reserves. This profit miss is what pushed the stock down.

    The earnings miss and margin drop are the main new financial event driving the stock lower this period.

  • Revenue beat and raised guidance Revenue rose 38% to $753.2 million, beating the roughly $699 million analysts expected, and the company raised its full-year revenue outlook to $3.1 billion to $3.3 billion. This shows demand is still strong, but investors focused on the loss and costs, so the stock still fell.

    It is the positive counterweight in the same earnings report and explains why the selloff was not larger.

  • CEO defends FTC lawsuit, touts cheaper GLP-1s CEO Andrew Dudum said the FTC lawsuit is more about publicity than a real resolution, and he expects cash-paying patients to eventually pay $40 to $50 a month for branded weight-loss drugs, down from $150 to $200. Cheaper pricing could boost demand, but the lawsuit still threatens fines and trust.

    It updates the biggest legal overhang and gives a concrete path to lower prices that could help future demand.

  • Weight-loss pill market cost pressure Hims & Hers and Novo Nordisk both fell even after strong growth, as investors worried about rising costs in the weight-loss pill market. Novo Nordisk's Wegovy pill sales missed expectations, adding to concerns that the branded GLP-1 push may be less profitable than hoped.

    It shows the cost and competition pressure in the core weight-loss business that is weighing on HIMS shares.

July 2026
▲2▼2

HIMS: FTC privacy lawsuit and law firm probes hit growth story

  • GLP-1 inflection and FDA peptide decision Barclays raised its price target to $39, citing a clear pickup in Hims & Hers' GLP-1 weight-loss business after the Novo Nordisk partnership, with website traffic up 35% and app users up 21%. A July FDA committee decision on peptides could open another growth avenue.

    This is the main positive force behind the stock and explains why it had been rising before the FTC news.

  • Novo Nordisk deal and Eucalyptus acquisition expand reach Hims & Hers is deepening its move into prescription weight management by offering Novo Nordisk's Wegovy and Ozempic, and its Eucalyptus acquisition adds scale in the UK, Australia, and Canada. This broadens revenue sources but raises questions about margins and regulatory exposure.

    It shows the concrete business expansion driving the growth narrative, a key reason investors were optimistic.

  • FTC lawsuit over data sharing and billing The FTC sued Hims & Hers, alleging it shared users' health data with advertisers like Meta and Snap and used deceptive billing and cancellation practices. The stock fell about 14.7% on the news, as the lawsuit threatens fines, reputational damage, and its core trust-based business model.

    This is the biggest new negative event and the main reason the stock dropped sharply this period.

  • Multiple law firm investigations into securities law violations Several law firms, including Holzer & Holzer, Frank R. Cruz, Kessler Topaz, and Lowey Dannenberg, are investigating whether Hims & Hers misled investors about the FTC allegations. These probes can lead to class-action lawsuits, adding legal costs and uncertainty that weigh on the stock.

    It shows the FTC issue is escalating into potential investor lawsuits, a fresh negative overhang.

▲2▼2

HIMS: FTC privacy lawsuit and law firm probes hit growth story

  • GLP-1 inflection and FDA peptide decision Barclays raised its price target to $39, citing a clear pickup in Hims & Hers' GLP-1 weight-loss business after the Novo Nordisk partnership, with website traffic up 35% and app users up 21%. A July FDA committee decision on peptides could open another growth avenue.

    This is the main positive force behind the stock and explains why it had been rising before the FTC news.

  • Novo Nordisk deal and Eucalyptus acquisition expand reach Hims & Hers is deepening its move into prescription weight management by offering Novo Nordisk's Wegovy and Ozempic, and its Eucalyptus acquisition adds scale in the UK, Australia, and Canada. This broadens revenue sources but raises questions about margins and regulatory exposure.

    It shows the concrete business expansion driving the growth narrative, a key reason investors were optimistic.

  • FTC lawsuit over data sharing and billing The FTC sued Hims & Hers, alleging it shared users' health data with advertisers like Meta and Snap and used deceptive billing and cancellation practices. The stock fell about 14.7% on the news, as the lawsuit threatens fines, reputational damage, and its core trust-based business model.

    This is the biggest new negative event and the main reason the stock dropped sharply this period.

  • Multiple law firm investigations into securities law violations Several law firms, including Holzer & Holzer, Frank R. Cruz, Kessler Topaz, and Lowey Dannenberg, are investigating whether Hims & Hers misled investors about the FTC allegations. These probes can lead to class-action lawsuits, adding legal costs and uncertainty that weigh on the stock.

    It shows the FTC issue is escalating into potential investor lawsuits, a fresh negative overhang.

Laboratory Corporation of America Holdings (LH)

Q3 2026
▲2▼1

Labcorp launches new tests, raises guidance, but Medicare fee cut proposal weighs

  • New product launches and Medicare coverage Labcorp launched ColoSense, the first FDA-approved at-home RNA colorectal cancer test, gained Medicare coverage for NASHnext, and introduced the first FDA-cleared Alzheimer's blood test. These expand its testing menu and open new revenue streams.

    These launches are new in Q3 and show innovation driving growth.

  • Strong financial performance and raised guidance Labcorp beat Q2 estimates, raised its 2026 guidance, completed a large buyback, and set long-term revenue growth targets of 5%–8%. This signals confidence in its business and returns cash to shareholders.

    These are new financial updates that positively influenced investor sentiment.

  • Proposed Medicare lab fee cuts CMS proposed cutting Medicare lab fees by up to 15% starting January 2027, citing overpayment versus private insurers. This sharply pressured Labcorp and Quest shares, raising concerns about future margins and revenue.

    This is a new regulatory threat that negatively impacted the stock.

  • Reaffirmed outlook despite reimbursement pressure Labcorp reaffirmed its 2026–2029 outlook, saying it already assumed reimbursement pressure. However, the stock still fell about 3% in Q3, reflecting investor caution over potential margin and revenue risks.

    This shows the counterweight: management confidence versus market skepticism.

September 2026
▲2▼1

New Alzheimer's Test and Growth Plan Meet Medicare Fee Cut Threat

  • First FDA-cleared single-biomarker Alzheimer's blood test Labcorp launched the first FDA-cleared single-biomarker Alzheimer's blood test, a simple blood draw that could replace costly PET scans. It also allied with the largest US primary care network to drive routine orders, supporting future test volume and revenue.

    New product and partnership that can lift future demand and revenue.

  • Investor Day reaffirms 2026 guidance and sets 5%-8% growth target Labcorp reaffirmed 2026 adjusted EPS guidance above Wall Street estimates and set long-term targets of 5%-8% annual revenue growth and 8.5%-11.5% EPS growth through 2029. The plan includes margin expansion and AI/robotics, giving investors a clearer growth path.

    Directly supports earnings expectations and long-term valuation.

  • CMS proposes up to 15% cut in Medicare lab fees CMS proposed cutting Medicare lab payments by up to 15% starting January 2027, saying Medicare pays 16% more than private insurers. Labcorp and Quest shares fell sharply. If finalized, this would lower reimbursement for routine tests and pressure revenue and margins.

    A major regulatory threat that directly reduces future payments.

  • Labcorp says CMS cuts won't change 2026-2029 outlook Labcorp reaffirmed its 2026-2029 growth targets despite the proposed Medicare cuts, saying it already accounted for continued reimbursement pressure. It warned the cuts could hurt patient access and backs the RESULTS Act. The stock still fell about 3%, showing investors remain cautious.

    Company response to the cut is key to whether the negative is already priced in.

Latest
▲2▼1

New Alzheimer's Test and Growth Plan Meet Medicare Fee Cut Threat

  • First FDA-cleared single-biomarker Alzheimer's blood test Labcorp launched the first FDA-cleared single-biomarker Alzheimer's blood test, a simple blood draw that could replace costly PET scans. It also allied with the largest US primary care network to drive routine orders, supporting future test volume and revenue.

    New product and partnership that can lift future demand and revenue.

  • Investor Day reaffirms 2026 guidance and sets 5%-8% growth target Labcorp reaffirmed 2026 adjusted EPS guidance above Wall Street estimates and set long-term targets of 5%-8% annual revenue growth and 8.5%-11.5% EPS growth through 2029. The plan includes margin expansion and AI/robotics, giving investors a clearer growth path.

    Directly supports earnings expectations and long-term valuation.

  • CMS proposes up to 15% cut in Medicare lab fees CMS proposed cutting Medicare lab payments by up to 15% starting January 2027, saying Medicare pays 16% more than private insurers. Labcorp and Quest shares fell sharply. If finalized, this would lower reimbursement for routine tests and pressure revenue and margins.

    A major regulatory threat that directly reduces future payments.

  • Labcorp says CMS cuts won't change 2026-2029 outlook Labcorp reaffirmed its 2026-2029 growth targets despite the proposed Medicare cuts, saying it already accounted for continued reimbursement pressure. It warned the cuts could hurt patient access and backs the RESULTS Act. The stock still fell about 3%, showing investors remain cautious.

    Company response to the cut is key to whether the negative is already priced in.

July 2026
▲4

Labcorp's new tests and raised guidance drive positive outlook

  • New at-home colorectal cancer test Labcorp launched ColoSense, the first FDA-approved RNA-based at-home colorectal cancer screening test, now covered by Medicare. This expands its test menu and could add recurring revenue from a large screening market.

    New product launch with Medicare coverage directly supports future revenue growth.

  • Medicare coverage for NASHnext liver test Medicare will cover and reimburse Labcorp's NASHnext blood test for liver disease starting August 2026, at about $252 per test. This should boost test volume and create a new recurring revenue stream.

    New reimbursement approval expands market access and revenue potential.

  • Raised profit forecast on strong testing demand Labcorp beat Q2 estimates and raised its 2026 earnings and revenue guidance, driven by steady diagnostic testing and growth in drug-development services. This signals management confidence and supports a higher stock price.

    Upgraded guidance and earnings beat are key positive catalysts for the stock.

  • Expanded oncology testing and buyback Labcorp launched the first FDA-approved PTEN companion diagnostic for prostate cancer and completed a large share buyback. These moves strengthen its precision oncology position and return cash to shareholders, supporting the stock.

    New oncology test and buyback completion reinforce growth and shareholder value.

▲4

Labcorp's new tests and raised guidance drive positive outlook

  • New at-home colorectal cancer test Labcorp launched ColoSense, the first FDA-approved RNA-based at-home colorectal cancer screening test, now covered by Medicare. This expands its test menu and could add recurring revenue from a large screening market.

    New product launch with Medicare coverage directly supports future revenue growth.

  • Medicare coverage for NASHnext liver test Medicare will cover and reimburse Labcorp's NASHnext blood test for liver disease starting August 2026, at about $252 per test. This should boost test volume and create a new recurring revenue stream.

    New reimbursement approval expands market access and revenue potential.

  • Raised profit forecast on strong testing demand Labcorp beat Q2 estimates and raised its 2026 earnings and revenue guidance, driven by steady diagnostic testing and growth in drug-development services. This signals management confidence and supports a higher stock price.

    Upgraded guidance and earnings beat are key positive catalysts for the stock.

  • Expanded oncology testing and buyback Labcorp launched the first FDA-approved PTEN companion diagnostic for prostate cancer and completed a large share buyback. These moves strengthen its precision oncology position and return cash to shareholders, supporting the stock.

    New oncology test and buyback completion reinforce growth and shareholder value.

© 2026 MarketIVWhy